ArticleGenetics in medicine : official journal of the American College of Medical Genetics2021
Patients dispensed medications with actionable pharmacogenomic biomarkers: rates and characteristics.
Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Insights Into Patient-Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline.Clinical pharmacology and therapeutics · 2026Article
- Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People.Journal of the American Geriatrics Society · 2025Article
- Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland.The pharmacogenomics journal · 2025Article
- Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.Clinical pharmacology and therapeutics · 2025Article
- Pharmacogenomics and Big Data in medical oncology: developments and challenges.Therapeutic advances in medical oncology · 2024Review
- A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China.Journal of clinical laboratory analysis · 2023Article
- Pharmacogenomic testing and prescribing patterns for patients with cancer in a large national precision medicine cohort.Journal of medical genetics · 2023Observational
- Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis.The pharmacogenomics journal · 2022Article
- Precision Medicine Landscape of Genomic Testing for Patients With Cancer in the National Institutes of Health All of Us Database Using Informatics Approaches.JCO clinical cancer informatics · 2022Observational
- Documenting Pharmacogenomic Test Results in Electronic Health Records: Practical Considerations for Primary Care Teams.Journal of personalized medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposePharmacogenomic biomarkers are increasingly listed on medication labels and authoritative guidelines but pharmacogenomic-guided prescribing is not yet common. Our objective was to assess the potential for incorporating knowledge of patients' genomic characteristics into prescribing practices.
methodsWe performed a retrospective analysis of claims data for 2,096,971 beneficiaries with pharmacy coverage from a national, commercial health insurance plan between January 2017 and December 2019. Children between 0 and 17 years comprised 21% of the cohort. Adults were age 18 to 64. Medications with actionable pharmacogenomic biomarkers (MAPBs) were identified using public information from the US Food and Drug Administration (FDA), Clinical Pharmacogenomics Implementation Consortium (CPIC), and PharmGKB.
resultsMAPBs were dispensed to 63% of the adults and 29% of the children in the cohort. Most frequently dispensed were ibuprofen, ondansetron, codeine, and oxycodone. Most common were medications with CYP2D6, G6PD, or CYPC19 pharmacogenomic biomarkers. Ten percent of the cohort were codispensed more than one MAPB for at least 30 days.
conclusionThe number of people who might benefit from pharmacogenomic-guided prescribing is substantial. Future work should address obstacles to integrating genomic data into prescriber workflows, complex factors contributing to the magnitude of benefit, and the clinical availability of reliable on-demand or pre-emptive pharmacogenomic testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.